Guggenheim lowered the firm’s price target on Twist Bioscience (TWST) to $50 from $58 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for several companies in its Diagnostics and Life Sciences Tools coverage to reflect recent updates from the companies after meetings with management teams.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience Stockholders Approve Key Amendments
- Cathie Wood’s ARK Investment bought 268K shares of Twist Bioscience today
- Twist Bioscience: Hold Rating Maintained Amidst Growth Concerns and Competitive Pressures
- Twist Bioscience price target raised to $62 from $54 at Scotiabank
- Twist Bioscience price target raised to $54 from $48 at Baird
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue